|
KMID : 1177320210240010001
|
|
Korean Journal of Schizophrenia Research
2021 Volume.24 No. 1 p.1 ~ p.7
|
|
|
Current Status of Clozapine for Treatment-Resistant Schizophrenia
|
|
Kim Se-Hyun
|
|
|
Abstract
|
|
|
|
Clozapine is the first and most effective atypical antipsychotic drug for treatment-resistant schizophrenia (TRS). After withdrawal of clozapine due to concerns of agranulocytosis, clozapine was reintroduced with a comprehensive safety monitoring system, the clozapine patient monitoring system (CPMS). The reintroduction was a response to the pressure from psychiatrists and patients with TRS and their families. Clozapine is still the best single agent for the treatment of TRS. However, approximately 30% of patients with TRS still show psychotic symptoms. In patients with clozapine-resistant schizophrenia (CRS), augmentation of other antipsychotic agents could be considered after a thorough evaluation of proper clozapine treatment. In this review, the status of clozapine in patients with TRS and CRS will be discussed.
|
|
|
KEYWORD
|
|
|
Antipsychotics, Clozapine, Schizophrenia, Treatment-resistant schizophrenia
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|